Identification of synthetic and natural host defense peptides with leishmanicidal activity

Alexandra K. Marr, S. Cen, R. E.W. Hancock, W. R. McMaster

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Leishmania parasites are a major public health problem worldwide. Effective treatment of leishmaniasis is hampered by the high incidence of adverse effects to traditional drug therapy and the emergence of resistance to current therapeutics. A vaccine is currently not available. Host defense peptides have been investigated as novel therapeutic agents against a wide range of pathogens. Here we demonstrate that the antimicrobial peptide LL-37 and the three synthetic peptides E6, L-1018, and RI-1018 exhibit leishmanicidal activity against promastigotes and intramacrophage amastigotes of Leishmania donovani and Leishmania major. We also report that the Leishmania protease/virulence factor GP63 confers protection to Leishmania from the cytolytic properties of all L-form peptides (E6, L-1018, and LL-37) but not the D-form peptide RI-1018. The results suggest that RI-1018, E6, and LL-37 are promising peptides to develop further into components for antileishmanial therapy.

Original languageEnglish
Pages (from-to)2484-2491
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number4
DOIs
Publication statusPublished - 1 Apr 2016

Fingerprint

Leishmania
Peptides
L Forms
Leishmania major
Leishmania donovani
Leishmaniasis
Virulence Factors
Therapeutics
Parasites
Peptide Hydrolases
Vaccines
Public Health
Drug Therapy
Incidence
peptide L

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Identification of synthetic and natural host defense peptides with leishmanicidal activity. / Marr, Alexandra K.; Cen, S.; Hancock, R. E.W.; McMaster, W. R.

In: Antimicrobial Agents and Chemotherapy, Vol. 60, No. 4, 01.04.2016, p. 2484-2491.

Research output: Contribution to journalArticle

@article{1d6d36abdad64726a2e940f3b8aa633a,
title = "Identification of synthetic and natural host defense peptides with leishmanicidal activity",
abstract = "Leishmania parasites are a major public health problem worldwide. Effective treatment of leishmaniasis is hampered by the high incidence of adverse effects to traditional drug therapy and the emergence of resistance to current therapeutics. A vaccine is currently not available. Host defense peptides have been investigated as novel therapeutic agents against a wide range of pathogens. Here we demonstrate that the antimicrobial peptide LL-37 and the three synthetic peptides E6, L-1018, and RI-1018 exhibit leishmanicidal activity against promastigotes and intramacrophage amastigotes of Leishmania donovani and Leishmania major. We also report that the Leishmania protease/virulence factor GP63 confers protection to Leishmania from the cytolytic properties of all L-form peptides (E6, L-1018, and LL-37) but not the D-form peptide RI-1018. The results suggest that RI-1018, E6, and LL-37 are promising peptides to develop further into components for antileishmanial therapy.",
author = "Marr, {Alexandra K.} and S. Cen and Hancock, {R. E.W.} and McMaster, {W. R.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1128/AAC.02328-15",
language = "English",
volume = "60",
pages = "2484--2491",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Identification of synthetic and natural host defense peptides with leishmanicidal activity

AU - Marr, Alexandra K.

AU - Cen, S.

AU - Hancock, R. E.W.

AU - McMaster, W. R.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Leishmania parasites are a major public health problem worldwide. Effective treatment of leishmaniasis is hampered by the high incidence of adverse effects to traditional drug therapy and the emergence of resistance to current therapeutics. A vaccine is currently not available. Host defense peptides have been investigated as novel therapeutic agents against a wide range of pathogens. Here we demonstrate that the antimicrobial peptide LL-37 and the three synthetic peptides E6, L-1018, and RI-1018 exhibit leishmanicidal activity against promastigotes and intramacrophage amastigotes of Leishmania donovani and Leishmania major. We also report that the Leishmania protease/virulence factor GP63 confers protection to Leishmania from the cytolytic properties of all L-form peptides (E6, L-1018, and LL-37) but not the D-form peptide RI-1018. The results suggest that RI-1018, E6, and LL-37 are promising peptides to develop further into components for antileishmanial therapy.

AB - Leishmania parasites are a major public health problem worldwide. Effective treatment of leishmaniasis is hampered by the high incidence of adverse effects to traditional drug therapy and the emergence of resistance to current therapeutics. A vaccine is currently not available. Host defense peptides have been investigated as novel therapeutic agents against a wide range of pathogens. Here we demonstrate that the antimicrobial peptide LL-37 and the three synthetic peptides E6, L-1018, and RI-1018 exhibit leishmanicidal activity against promastigotes and intramacrophage amastigotes of Leishmania donovani and Leishmania major. We also report that the Leishmania protease/virulence factor GP63 confers protection to Leishmania from the cytolytic properties of all L-form peptides (E6, L-1018, and LL-37) but not the D-form peptide RI-1018. The results suggest that RI-1018, E6, and LL-37 are promising peptides to develop further into components for antileishmanial therapy.

UR - http://www.scopus.com/inward/record.url?scp=84963716961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963716961&partnerID=8YFLogxK

U2 - 10.1128/AAC.02328-15

DO - 10.1128/AAC.02328-15

M3 - Article

VL - 60

SP - 2484

EP - 2491

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -